home / stock / vvos / vvos news

VVOS News and Press, Vivos Therapeutics Inc. From 03/08/22

Stock Information
Company Name: Vivos Therapeutics Inc.
Stock Symbol: VVOS
Market: NASDAQ
Website: vivoslife.com
Menu
VVOS VVOS Quote VVOS Short VVOS News VVOS Articles VVOS Message Board
Get VVOS Alerts

News, Short Squeeze, Breakout and More Instantly...
VVOS - InvestorNewsBreaks - Vivos Therapeutics Inc. (NASDAQ: VVOS) Selected Among 'World's Most Innovative Companies' by Fast Company Magazine

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snorin...
VVOS - Fast Company Selects Vivos Therapeutics for 2022 "World's Most Innovative Companies" List

HIGHLANDS RANCH, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or “the Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities ...

VVOS - Vivos Therapeutics: First Take After The Broad Market Sell-Off

Vivos Therapeutics, Inc. markets a jaw repositioning device that has the potential to cure patients’ mild-to-moderate obstructive sleep apnea. Despite an active 2021 that saw its mmRNA oral appliance cleared as a Level II device – prompting gains in insurance coverage (i...

VVOS - InvestorNewsBreaks - Vivos Therapeutics Inc. (NASDAQ: VVOS) Rebrands Proprietary Offering of Clinical Treatment Devices, Modalities and Protocols

Vivos Therapeutics (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snorin...
VVOS - Vivos Therapeutics Rebrands Proprietary Clinical Protocol for Treating Patients with Breathing and Sleep Disorders

HIGHLANDS RANCH, Colo., March 03, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities ...

VVOS - InvestorNewsBreaks - Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Plans to Participate in Investor Conferences

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (“OSA”) and snoring,...

VVOS - Vivos Therapeutics to Participate in Upcoming Investor Conferences

HIGHLANDS RANCH, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities ...
VVOS - InvestorNewsBreaks - Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate in 2022 World Sleep Congress

Vivos Therapeutics (NASDAQ: VVOS) Medical Advisor Board has been invited to present at the upcoming World Sleep Congress. The event, slated for March 11–16, 2022, will be held in Rome. Members of the board will be presenting a summary review of sleep-therapy data from patients treat...

VVOS - Vivos Therapeutics to Present at March 2022 World Sleep Congress in Rome

HIGHLANDS RANCH, Colo., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients su...

VVOS - Aridis, Rhythm top healthcare gainers; 10x Genomics, iSpecimen lead losers pack

Gainers: Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. Outset Medical (NASDAQ:OM) +10%. Masimo (NASDAQ:MASI) +8%. Vivos Therapeutics (NASDAQ:VVOS) +7%. Losers: 10x Genomics (NASDAQ:TXG) -16%. iSpecimen ISPC -10%. Poseida ...
Previous 10 Next 10